


## ZLJ-6

<b>Cat. No.:</b>	HY-113807
<b>CAS No.:</b>	1051931-39-5
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>17</sub> N <sub>3</sub> O <sub>6</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	375
<b>Target:</b>	COX; Lipoxygenase
<b>Pathway:</b>	Immunology/Inflammation; Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	ZLJ-6 is a dual COX and 5-LOX inhibitor with oral activity. The IC <sub>50</sub> values for COX-1, COX-2 and 5-LOX were 0.73, 0.31 and 0.99 μM, respectively. ZLJ-6 has anti-inflammatory and analgesic activity <sup>[1][1]</sup> .										
<b>IC<sub>50</sub> &amp; Target</b>	COX-1 0.73 μM (IC <sub>50</sub> )	COX-2 0.31 μM (IC <sub>50</sub> )	5-LOX 0.99 μM (IC <sub>50</sub> )								
<b>In Vitro</b>	<p>ZLJ-6 (3, 10, 30 μM, 6 h) can effectively inhibit the expression of TNF-α-induced monocyte endothelial interaction and adhesion molecules (e-selectin, ICAM-1 and VCAM-1)<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HUVECs</td> </tr> <tr> <td>Concentration:</td> <td>3, 10, 30 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>6 h</td> </tr> <tr> <td>Result:</td> <td>Decreased NF-κB p65 subunit translocation to nucleus dose-dependently. Inhibited TNF-α-induced IκBα phosphorylation.</td> </tr> </table>			Cell Line:	HUVECs	Concentration:	3, 10, 30 μM	Incubation Time:	6 h	Result:	Decreased NF-κB p65 subunit translocation to nucleus dose-dependently. Inhibited TNF-α-induced IκBα phosphorylation.
Cell Line:	HUVECs										
Concentration:	3, 10, 30 μM										
Incubation Time:	6 h										
Result:	Decreased NF-κB p65 subunit translocation to nucleus dose-dependently. Inhibited TNF-α-induced IκBα phosphorylation.										
<b>In Vivo</b>	<p>ZLJ-6 (3, 10, 30 mg/kg, oral) shows effective anti-inflammatory activity in carrageenan-induced rat plantar edema model, and analgesic activity in acetic acid-induced mouse peritoneal constriction model<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>										

### REFERENCES

- [1]. Li L, et al. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. *Eur J Pharmacol.* 2009 Apr 1;607(1-3):244-50.
- [2]. Chen L, et al. ZLJ-6, a novel COX/5-LOX inhibitor, attenuates TNF-α-induced endothelial E-selectin, ICAM-1 and VCAM-1 expression and monocyte-endothelial interactions via a COX/5-LOX-independent mechanism. *Vascul Pharmacol.* 2011 Nov-Dec;55(5-6):135-42.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA